<DOC>
	<DOCNO>NCT00316849</DOCNO>
	<brief_summary>This phase I trial study side effect best dose temsirolimus give together temozolomide radiation therapy treat patient newly diagnose glioblastoma multiforme . Temsirolimus may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving temsirolimus together temozolomide radiation therapy may kill tumor cell .</brief_summary>
	<brief_title>Temsirolimus , Temozolomide , Radiation Therapy Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose temsirolimus administer temozolomide combination radiotherapy follow adjuvant temozolomide patient newly diagnose glioblastoma multiforme . II . Assess describe adverse event associate regimen patient . III . Evaluate early response therapy patient use automated morphological MRI change detector physiological MRI technique , include diffusion-weighted imaging , perfusion-weighted imaging , chemical shift image . SECONDARY OBJECTIVES : I . Determine inhibition status mTOR signal pathway peripheral blood mononuclear cell patient treat regimen . II . Identify potential pharmacokinetic interaction temozolomide temsirolimus . III . Correlate , preliminarily , survival , progression-free survival , response pre-treatment tumor tissue molecular marker patient . OUTLINE : This multicenter , dose-escalation study temsirolimus . Patients assign 1 2 treatment group . GROUP 1 : ( temsirolimus radiation temozolomide ) Patients receive temsirolimus IV 30 minute weekly . Beginning 7-10 day later , patient also receive oral temozolomide daily undergo concurrent 3-D conformal radiotherapy intensity-modulated radiotherapy daily , 5 day week , 6 week . Patients evaluate 4-6 week completion chemoradiotherapy . Patients stable respond disease proceed adjuvant therapy . Cohorts 3-6 patient receive escalate dos temsirolimus maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 6 patient treated MTD . GROUP 2 : ( radiation temozolomide ) Patients receive oral temozolomide daily undergo concurrent 3-D conformal radiotherapy intensity-modulated radiotherapy daily , 5 day week , 6 week . Patients evaluate 4-6 week completion chemoradiotherapy . Patients stable respond disease proceed adjuvant therapy . ADJUVANT THERAPY : Beginning 4-6 week completion chemoradiotherapy patient receive oral temozolomide day 1-5 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Some patient undergo blood collection immune monitoring translational/pharmacologic study . After completion study treatment , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologically confirm glioblastoma multiforme ( GBM ) Gliosarcoma grade 4 astrocytoma variant ( e.g. , giant cell glioblastoma ) allow Newly diagnose disease Has undergone surgical resection biopsy tumor least 1 week 6 week ago ECOG performance status 02 Absolute neutrophil count ≥ 1,500/mm^3 Hemoglobin ≥ 9.0 g/dL Platelet count ≥ 100,000/mm^3 Total bilirubin ≤ 2.5 time upper limit normal ( ULN ) Cholesterol &lt; 350 mg/dL Triglycerides &lt; 400 mg/dL AST ≤ 2.5 time ULN Creatinine ≤ 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history allergy intolerance dacarbazine No ongoing active infection No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No psychiatric illness social situation would preclude study compliance No uncontrolled illness No gastrointestinal tract disease affect ability take oral medication require IV alimentation No significant traumatic injury within past 21 day No active , uncontrolled peptic ulcer disease No active cancer require therapy No concurrent combination antiretroviral therapy HIVpositive patient Willing able comply antibiotic prophylaxis either trimethoprim/sulfamethoxazole ( daily 3 time per week ) monthly IV pentamidine combine daily levofloxacin No prior chemotherapy brain tumor No prior temozolomide mTOR inhibitor therapies No prior cranial radiotherapy More 21 day since prior major surgery ( exclude neurosurgical biopsy resection GBM ) No prior surgical procedure affect absorption No concurrent enzymeinducing anticonvulsant , include follow : Carbamazepine Phenytoin Phenobarbital Primidone No concurrent investigational agent Not receive warfarin prior study registration Concurrent warfarin allow patient develop indication enrol protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>